Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide
Table 3
Univariate Cox regression analysis of baseline patient characteristics for postprogression survival.
Factors
Postprogression survival
Hazard ratio
95% CI
value
Gender
Male/female
1.60
0.84–3.37
0.15
Age at the beginning of first-line treatment (years)
1.00
0.96–1.04
0.79
PS at the beginning of first-line treatment
1.11
0.86–1.42
0.40
Number of courses of first-line treatment administered
0.72
0.56–0.93
0.01
Best response at first-line treatment
PR/non-PR
0.39
0.22–0.71
<0.05
Non-PD/PD
0.55
0.30–1.08
0.08
PS at the end of first-line treatment
2.09
1.56–2.74
<0.001
Brain metastases at initial diagnosis
Yes/no
1.04
0.61–1.73
0.88
Type of relapse
Refractory/sensitive
4.28
2.03–10.25
<0.001
Age at the beginning of second-line treatment (years)
0.99
0.95–1.04
0.90
PS at the beginning of second-line treatment
2.49
1.59–3.92
<0.001
Best response at second-line treatment
PR/non-PR
0.34
0.17–0.67
<0.05
Non-PD/PD
0.22
0.09–0.56
<0.05
Administration of platinum rechallenge
Yes/no
0.51
0.28–0.88
<0.05
Administration of AMR
Yes/no
0.39
0.22–0.67
<0.001
Administration of TOP
Yes/no
0.32
0.11–0.77
<0.05
Reason for carboplatin + etoposide administration
Cardiorenal dysfunction/poor PS
0.82
0.49–1.36
0.44
Number of regimens administered following disease progression after the first-line chemotherapy
